Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 4/20 | 0.67 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.67 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.67 |
| ▸ | PGAM1 | P18669 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407933 | 1.00 | BCL2 (0.67) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL16226906 | 0.87 | MAOA (0.59) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL23199059 | 0.86 | ALDH1A1 (0.61) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL555230 | 0.80 | BCL2 (1.00) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL29384381 | 0.80 | BCL2 (1.00) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL29388375 | 0.80 | BCL2 (1.00) | BCL2MCL1MAPTALDH1A1LCK | |
| Damnacanthal SCHEMBL29356591 | 0.80 | MAPT (1.00) | BCL2MCL1MAPTALDH1A1LCK | |
| Damnacanthal SCHEMBL147246 | 0.80 | MAPT (1.00) | BCL2MCL1MAPTALDH1A1LCK | |
| SCHEMBL15676390 | 0.79 | MAPT (0.54) | BCL2MCL1MAPTALDH1A1LCK | |
| Rubiadin SCHEMBL22616292 | 0.76 | BCL2 (0.71) | BCL2MCL1MAPTALDH1A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
| US-20170298209-A1 | USE OF A QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2017-10-19 | — | — | US | disclosed |
| US-20150208657-A1 | USE OF QUINONE COMPOUND IN BUILDING MATERIALS | ARKION LIFE SCIENCES, LLC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | BCL2 842/4885MCL1 599/4885MAPT 3619/4885 |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | BCL2 2450/4885MCL1 2381/4885MAPT 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.